Arrowhead Pharmaceuticals targets Q3 topline data for SHASTA-3/4 and a supplemental NDA submission by year-end 2026.
Arrowhead Pharmaceuticals announced plans to release topline data for its SHASTA-3/4 programs in Q3 2026. The company also aims to file a supplemental new drug application (sNDA) for SHTG before the end of the year.
Management stated the company is now commercial and reported approximately 30 new prescriptions written per week. This follows a period of strategic expansion and operational strengthening, positioning Arrowhead for growth.
The updates were shared during the company’s Q2 2026 earnings call, reflecting confidence in its pipeline and commercial progress.